Loading…
Loading…
Are her big ideas turning into big returns?
The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc's (NYSE:MRK) positive Phase 3 results for a personalized mRNA cancer vaccine could revive investor interest in genomics, immunotherapy and precision medicine ETFs.
August delivered strong gains across shipping, crypto, precious metals, biotech, copper, uranium and cloud software ETFs.
Ark Invest was a buyer of tech stocks down as much as 53% from their recent all-time highs.
ARK Genomic Revolution ETF remains a buy as its valuation improves and technical support emerges after a 15% correction from July highs. ARKG's portfolio is concentrated in small- and mid-cap biotech, with top 10 holdings comprising 59% and a long-term EPS growth rate now at 10.7%. Despite weak seasonality and high volatility, ARKG's rising 200-day moving average and strong support at $34–$35 provide a favorable risk-reward setup.
The ARK Genomic Revolution ETF (CBOE:ARKG) and the Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) look like siblings on any screener.
Biotech, China, insurance and healthcare ETFs led June gains as strong earnings, AI optimism and easing geopolitical fears lifted markets.
June has been a month full of excitement in the ETF market. While commercial space and AI infrastructure attracted a significant amount of investor attention, biotechnology exposure comprises four out of the five top-performing equity ETFs as of June 29.